Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa · Seattle Cancer Care Alliance · +30 more institutions
Abstract
The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions and ASCO, consisting of medical and hematologic oncologists with expertise in a wide array of disease sites, and experts from the fields of dermatology, gastroenterology, neuro-oncology, nephrology, emergency medicine, cardiology, oncology nursing, and patient advocacy. Several panel representatives are members of the Society for Immunotherapy of Cancer (SITC). The initial version…
Citation impact
- FWCI
- 37.09
- Percentile
- 100%
- References
- 209
Authors
31- JAJohn A. ThompsonCorresponding
Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa, Seattle Cancer Care Alliance, Fred Hutch Cancer Center, Cancer Research Center
- BJBryan J. Schneider
University of Michigan
- JRJulie R. Brahmer
Sidney Kimmel Comprehensive Cancer Center
- SAStephanie Andrews
Moffitt Cancer Center
- PAPhilippe Armand
Dana-Farber Brigham Cancer Center
Topics & keywords
- Medicine
- Immunotherapy
- Internal medicine
- Oncology
- Cancer
- Cancer immunotherapy
- Chimeric antigen receptor
- Alternative medicine
- Good health and well-being